US-Listed Biological Products, (No Diagnostic Substances) — Revenue Percentiles, FY 2023

Population: 121 US-listed companies (SIC 2836), fiscal year 2023; fiscal year ends 2023-06-30 to 2024-04-30.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$0
25th percentile	$488.0k
Median	$14.0M
75th percentile	$78.6M
90th percentile	$371.2M
Mean	$714.8M
Minimum	$0
Maximum	$28.2B

Methodology & sources
Revenue as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2023 = fiscal years ending 2023-06-01 to 2024-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Revenue percentiles (live) · All Biological Products, (No Diagnostic Substances) benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2836/revenue/2023